Open access peer-reviewed chapter

Uremic Retention Solutes

Written By

William Ackley, Leland Soiefer, Aleksey Etinger and Jerome Lowenstein

Submitted: 13 March 2017 Reviewed: 24 July 2017 Published: 20 December 2017

DOI: 10.5772/intechopen.70461

From the Edited Volume

Aspects in Dialysis

Edited by Ayman Karkar

Chapter metrics overview

1,189 Chapter Downloads

View Full Metrics


This chapter will address the broad subject of uremic retention solutes (URS), also known as uremic toxins. Some of these solutes had been recognized for decades, and in 1999 when the European Uremic Toxin Work Group was established, a fuller description of URS was presented. The group sought to identify and characterize the solutes in the serum of patients with impaired glomerular filtration, in order to explore their role in the pathogenesis of the uremic syndrome and improve current therapeutic options. This chapter will review the different types of URS, as well as the adverse effects associated with their accumulation. It will also cover current and potential therapeutic approaches to reduce their levels.


  • uremic retention solutes (URS)
  • uremic toxins
  • CKD
  • ESRD
  • indoxyl sulfate
  • p-cresyl sulfate
  • kynurenine

1. Introduction

Chronic kidney disease (CKD) is defined by estimated glomerular filtration rate (eGFR). Uremic syndrome occurs as this eGFR declines over time. Uremia is due to the accumulation of uremic retention solutes (URS) that affect multiple organ systems most notably the cardiovascular, neurologic, endocrine, and skeletal systems. These URS become elevated during the course of CKD and reach their peak during end-stage renal disease (ESRD). Organ dysfunction due to URS is seen, at times, long before patients reach the stage of dialysis dependency. Patients with early stages of CKD are much more likely to die from cardiovascular disease than to progress to ESRD [1]. While accelerated cardiovascular disease in patients undergoing chronic hemodialysis has been attributed to traditional cardiovascular risk factors, e.g., hypertension, diabetes, and lipid abnormalities, Lindner identified an accelerated risk of atherosclerosis in CKD patients without these risk factors [2]. During the past 10 years, there has been growing interest in characterizing the relationship between URS and cardiovascular disease. Since accelerated cardiovascular disease is seen in well-dialyzed patients, attention has been focused on solutes that are poorly dialyzed. Protein-bound URS, specifically indoxyl sulfate and p-cresyl sulfate, have been the focus of many studies over the past several decades. The interest is a result of their strong association with cardiovascular disease, their poor dialyzability, and their propensity to act on receptors (organic anion transporters) on the endothelium. Many different strategies for enhancing their removal and novel methods for reducing their generation have evolved over this period of time. The focus of this chapter will be to describe the classification of URS, describe their physiology, review their negative effects in the setting of uremia, and outline the different strategies currently being investigated to reduce levels of these solutes.


2. Classification of uremic retention solutes

The established classification system for URS is dependent on carrier protein binding and molecular weight [3]. The first class, termed low molecular weight (LMW) solutes, is categorized as less than 500 Da and is efficiently removed via hemodialysis. The next class is known as middle molecular weight (MMW) solutes. These molecules have molecular weights greater than 500 Da and require high-flux dialysis membranes, which have greater transport capacity and larger pore size for removal [4]. Protein-bound solutes comprise the last group, which are typically less than 500 Da though there is no official size demarcation. Their defining feature is their limited dialytic removal due to protein binding that impedes their movement across a dialysis membrane. A brief survey of LMW and MMW solutes will be given before focusing more in depth on the protein-bound solutes.

2.1. Low molecular weight solutes

Some of the most prominent examples of the LMW category are urea, creatinine, asymmetric dimethylarginine (ADMA), trimethylamine-N-oxide (TMAO), and uric acid.

Urea has long been known to be elevated in patients with acute and chronic kidney diseases (Table 1). Today, urea levels are used as a surrogate for kidney function and for assessing the adequacy of hemodialysis sessions [5]. However, the data that has been gathered over the past several decades has been conflicting over whether urea is harmful or inert [6]. While research has shown that increasing the plasma levels of urea to ten times the upper limit can produce moderate uremic symptoms (lethargy and headache), there is no evidence of a survival benefit with aggressive reductions in urea during dialysis [7, 8]. In vitro and in vivo studies have linked urea to gut epithelial damage, endothelial dysfunction, and vascular smooth muscle apoptosis [6, 9]. Despite this data, it is difficult to determine the true effect of urea reduction on uremic syndrome and patient survival due to numerous confounding factors [6].

MW (Da) Source Metabolism Toxicity
Urea [6] 60.05 Dietary proteins Hepatic Vascular disease, insulin resistance (in vivo data)
ADMA [24] 202.25 Protein metabolism Endogenous enzymes Vascular disease
TMAO [15] 75.11 Diet Hepatic Vascular disease, renal fibrosis
Uric acid [18, 19, 20] 168.11 Purine metabolism Endogenous enzymes Accelerated CKD, vascular disease, hypertension

Table 1.

Low molecular weight URS.

URS, uremic retention solutes; MW, molecular weight; ADMA, asymmetric dimethylarginine; TMAO, trimethylamine-N-oxide

Creatinine is formed from creatine, as part of the metabolic breakdown of the muscle. Clinically, serum creatinine levels are used to estimate glomerular filtration rate (eGFR) [10]. In CKD, creatinine accumulates as a result of decreased renal clearance, but no compelling evidence has linked it to pathology in kidney disease.

Two other LMW solutes (Table 1) with possible links to the pathophysiology of cardiovascular disease in CKD patients are asymmetric dimethylarginine (ADMA) and trimethylamine-N-oxide (TMAO). ADMA has been shown to inhibit nitric oxide synthase causing endothelial dysfunction and has been correlated with vascular damage as evidenced by increased vessel wall thickness [3, 11, 12]. For ADMA, removal strategies (other than dialysis) have focused on the enzyme dimethylaminohydrolase. Inhibition of this enzyme has been linked to ADMA accumulation, whereas enzyme upregulation has shown decreased coronary damage in mice [13, 14]. TMAO is a small amine oxide with a well-documented association with cardiovascular disease [15]. However, the mechanism by which it leads to atherosclerosis remains speculative with research focusing on endothelial adhesion molecule dysfunction [15, 16]. Considering that the removal of TMAO via dialysis is already highly efficient, therapeutic strategies have targeted the generation of TMAO by the gut microbiome [17].

Uric acid is a LMW molecule (Table 1) that is generated as a result of purine metabolism. Most animals, with the exception of humans and other primates, break down uric acid utilizing the enzyme uricase. Humans lack this enzyme and therefore excrete uric acid via the gut and kidney. Elevated uric acid levels are implicated in the pathophysiology of gout, but it has been proposed that it also plays a role in cardiovascular disease among the CKD population. Numerous studies have looked at the relationship of uric acid on cardiovascular events and mortality in the setting of early CKD [18, 19, 20]. The results have not been consistent, and this topic remains controversial. Hyperuricemia is believed to cause chronic stimulation of the renin angiotensin system leading to hypertension and progressive kidney disease [21]. Numerous randomized controlled trials have been conducted to determine whether the administration of urate-lowering therapy has an effect on CKD progression [22, 23]. There is a trend toward benefit, but it remains controversial due to significant heterogeneity among study groups and a lack of blinded studies.

2.2. Middle molecular weight (MMW) solutes

These solutes range from a MW of 500 to many tens of thousands of Daltons (Da). It is difficult at times to differentiate between solutes that are elevated due to reduced renal excretion (such as β2-microglobulin and leptin) versus those that are elevated due to other reasons (such as parathyroid hormone (PTH), fibroblast growth factor-23 (FGF-23), and advanced glycation end products (AGEP), among others). This section will focus on the former group.

The most prominently studied MMW solute is β2-microglobulin (Table 2), an important component of the major histocompatibility complex [4]. β2-Microglobulin is recognized to be related to the deposition of amyloid in bones and joints. Speculation exists that it is not only a URS marker but additionally plays an active role in cardiovascular damage [25]. The removal of MMW solutes has centered on high-flux membranes containing wider pores to accommodate these larger molecules. However, the survival benefit of high flux versus low flux has not been definitively demonstrated in the dialysis population [26].

MW (Da) Source Toxicity
β2-Microglobulin [25] 11,729 Major histocompatibility complex Amyloid bone and joint disease, vascular wall infiltration
Leptin [28] 16,000 Endogenous Malnutrition

Table 2.

Middle molecular weight URS.

URS, uremic retention solutes; MW, molecular weight

The discovery of the obesity gene in 1994 and its subsequent protein product, leptin, was an important step in understanding obesity [27]. Leptin accumulates in CKD/ESRD (Table 2). It is produced by white adipose tissue in response to an increase in body fat. It is found in a free form as well as bound to leptin-soluble receptor, which has a molecular weight of >150,000 Da. Exogenous administration of leptin, in an in vitro study, led to a reduction in food intake, increased energy expenditure, and a subsequent decrease in body weight [28]. Leptin is predominantly cleared by the kidneys, and it has been demonstrated that chronic hemodialysis patients have supraphysiological levels of this protein [29]. Using a mouse model, in which uremia was induced via subtotal nephrectomy, it has been demonstrated that the level of malnutrition was lower in leptin-receptor-deficient mice compared to wild-type mice [30].

2.3. Protein-bound solutes

Protein-bound URS are generally <500 Da. As mentioned earlier, protein-bound URS are poorly dialyzable due to their high affinity for carrier proteins such as albumin. Albumin binding is complex and determined by numerous factors that are not fully understood. This section will focus on two binding sites found on albumin, Sudlow’s sites I and II, which were first described in 1975 [31]. Sudlow’s site I is also known as the warfarin site, and Sudlow’s site II is the diazepam site. But there are numerous drugs and URS that bind to these sites. Sudlow’s site I is the binding site of 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF), indomethacin, salicylates, and many others. 3-Carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) is considered to be one of the most potent inhibitors of drug binding to albumin compared to other URS [32, 33]. Sudlow’s site II is the binding site of IS, PCS, hippuric acid, and ibuprofen. Observational studies have demonstrated a link between indoxyl sulfate (IS) and p-cresyl sulfate (PCS) concentrations and increased cardiovascular morbidity and mortality in CKD/ESRD. Both of these compounds have a shared quality of possessing high affinity to Sudlow’s site II [34]. As such, they both exist primarily in the bound form (Table 3).

MW (Da) Source Metabolism Toxicity Percent unbound
Indoxyl sulfate [37, 38, 45, 46, 47, 48] 251.30 Tryptophan Gut microbiome, hepatic Cardiovascular ~10%
p-Cresyl sulfate [37, 38, 45, 46] 188.19 Tyrosine Gut microbiome, hepatic Cardiovascular 5–10%
Kynurenine [41, 42, 43] 208.21 Tryptophan Primarily hepatic, also immune cells CNS N/A
Kynurenic acid [41, 42, 43, 52] 189.17 Tryptophan CNS CNS 14%
Quinolinic acid [41, 44] 167.12 Tryptophan Brain microglia Bone marrow, CNS N/A
CMPF [38] 240.25 Furanoid fatty acids Endogenous enzymes Bone marrow, thyroid, albumin drug binding <1%

Table 3.

Protein-bound URS.

URS, uremic retention solutes; MW, molecular weight; CMPF, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid

There are known differences in the rate of production of protein-bound URS, and this likely explains why their plasma levels do not correlate well with creatinine, urea levels, or estimated GFR [3]. Organic anion transporters (OAT1 and OAT3) on the basolateral membrane of the proximal tubule are responsible for URS entry into the cell, and subsequent secretion into the tubular lumen appears to be mediated by OAT4 [35, 36, 37]. This important physiological process is hindered by nephron loss in advanced CKD and almost nonexistent in ESRD leading to significant elevation of protein-bound URS.

CMPF is a highly protein-bound URS (see Table 3). It is very poorly dialyzable, and there is in vitro data that it leads to radical oxygen species (ROS) production in endothelial cells. Unlike other protein-bound URS, CMPF does not demonstrate any significant removal during dialysis, but dialysate effluent levels were not measured to determine whether there is filtration [38]. The probable explanation, offered by the authors, for the paradoxical rise of CMPF levels after dialysis is hemoconcentration. CMPF has significant effects on drug binding to albumin. CMPF has also been implicated in numerous pathological pathways including anemia, hypothyroidism, and others [39, 40].

Tryptophan metabolism via the kynurenine pathway produces several solutes (including kynurenine and quinolinic acid) relevant to renal failure. In ESRD patients, elevated levels of kynurenine and quinolinic acid have been associated with endothelial dysfunction, inflammation, and carotid artery thickening [41]. Metabolic products of kynurenine, specifically kynurenic acid, are also known to have neural activity at several neurotransmitter receptors, and alterations in kynurenine removal are thought to be sufficient to produce CNS effects [42, 43]. Researchers have demonstrated that quinolinic acid inhibits erythropoietin release in vitro, possibly contributing to the anemia seen in ESRD patients [44].


3. The gut-kidney axis

Over the last few decades, microbial metabolism in the human gut has been recognized as offering beneficial effects to the host. These effects include fermentation of carbohydrates resistant to our own enzymatic processes, formation of several vitamins, and unique contributions to the mammalian metabolome [49, 50]. Important to the current discussion of uremic retention solutes is that a significant amount of protein-bound solutes (IS and PCS included) are formed by dietary protein metabolism in the large intestine [51]. In fact, a 2011 study with dialysis patients comparing the URS levels of individuals with a total colectomy versus those with an intact colon showed IS and PCS to be nearly absent in those patients without colons [52]. Similarly, IS and PCS levels are very low in germ-free rodents.

Protein metabolism in the large intestine generates IS and PCS along parallel pathways (Figure 1). For IS the process starts with dietary tryptophan being acted upon by bacterial tryptophanase enzymes that convert tryptophan to indole. Indole is then absorbed in the large intestine and travels to the liver where it is oxidized and sulfated to form indoxyl sulfate [53]. Similarly, bacterial metabolism of tyrosine generates p-cresyl, which is absorbed and converted to p-cresyl sulfate by the liver. Both IS and PCS become bound to albumin and circulate in the plasma until they are secreted by the kidneys via OATs found on the basolateral and luminal membranes of proximal renal tubular cells. The relationship between gut bacterial metabolites, normal human metabolism, and renal excretion has been termed the gut-kidney axis [51, 54, 55, 56]. In fact, an additional classification of URS has been proposed, organizing solutes based on their origin (human metabolism, microbial metabolism, or diet) as opposed to their behavior during dialysis [49].

Figure 1.

The gut-kidney axis of indoxyl sulfate (IS) and p-cresyl sulfate (PCS). Adapted from [55] with permission.

In addition to the colon microbiota species, the main determinants of gut microbial metabolism are diet and transit time [56]. With diet, the ratio of carbohydrate catabolism to protein catabolism by the microbiota determines the extent to which protein metabolism (and therefore URS generation) takes place. In the case of carbohydrate excess such as with a high-fiber diet, there is a large amount of energy available for bacterial growth and cell division. The nitrogen sources in the gut are consequently utilized for the bacteria’s own growth and replication as opposed to being fermented for energy [49]. However, in carbohydrate deficiency, the nitrogen sources are predominantly metabolized to phenols, indoles, and amines, thereby contributing to URS generation [51].

Another modifiable determinant of microbial metabolism is the colonic transit time. In vivo human data has demonstrated that the majority of the variance seen in the urinary phenol excretion rate was due to colonic transit time and dietary protein intake. In fact, a doubling of the colonic transit time corresponded to a 60% increase in urinary excretion of phenols [57]. It is thought that longer transit times induce the development of large populations of many proteolytic bacteria. This, in addition to the relative carbohydrate deficit in the colon, contributes to greater protein metabolism and URS generation [51, 56]. The role of the gut-kidney axis when considering possible therapeutics to lower URS will be discussed in a later section.


4. Effects on the cardiovascular system

Patients with CKD or ESRD have high morbidity and mortality from cardiovascular disease. Unfortunately, a patient with CKD is much more likely to die of cardiovascular disease than to reach the stage of dialysis dependency [1]. Due to their possible contribution to cardiovascular disease, indoxyl sulfate and p-cresyl sulfate have attracted a lot of research attention.

4.1. Indoxyl sulfate

A number of human studies have shown a clinical association between high indoxyl sulfate levels and various adverse outcomes. Especially in the early stages of CKD, there have been associations of higher IS levels with left ventricular dysfunction, coronary atherosclerosis, coronary stent restenosis, and cardiac death [58, 59, 60, 61]. However, with more advanced CKD (such as with hemodialysis patients), the associations of higher IS levels with cardiovascular events and cardiac death are mixed [62, 63, 64, 65]. Several studies specifically show no association between higher IS levels and cardiovascular morbidity and mortality [64, 65]. This might be related to the fact that with advanced CKD, there is already end organ damage, and so the levels of URS are not as significant.

Studies with isolated cells or tissues have demonstrated a number of mechanisms by which IS could possibly lead to cardiovascular disease. One of these mechanisms is via increased tissue factor expression. Multiple studies examining this feature have found evidence that IS acts as an agonist for the aryl hydrocarbon receptor (AHR) in vascular smooth muscle cells. The AHR-IS complex is translocated to the nucleus where it dysregulates a host of genes leading to inhibition of the degradation of tissue factor [66]. This concept was further demonstrated by showing that AHR antagonists reduce tissue factor expression [67]. Additionally, AHR activation has been linked to increased progression of atherosclerosis in a mouse model [68]. Another mechanism might be via leukocyte endothelial adhesion. Studies have demonstrated increased leukocyte recruitment with IS exposure, as well as increased leukocyte adhesion to endothelial cells which is accompanied by increased expression of NF-kB, TNFα, and E-selectin. IS pretreatment of endothelial cells significantly increased IL-1β–induced E-selectin expression, monocyte adhesion, and phosphorylation of various MAP kinases and transcription factors such as NF-kB [69]. These findings support the hypothesis that altered E-selectin shedding may play a central role in the cardiovascular disease that complicates the course of many CKD patients [70].

Additionally, increased vascular calcifications seem to accompany increased IS levels. In vivo rodent studies demonstrated that uremic-level IS administration resulted in vascular calcifications [71]. The mechanism by which IS leads to vascular calcification is unknown, but it may be related to altered osteoblast signaling [72]. Additional evidence regarding the effects of IS includes disrupted adherens junctions on endothelial cells, impaired proliferation and self-repair of endothelial cells, endothelial microparticle release, free radical production, and increased advanced glycation end products [73, 74, 75, 76, 77].

4.2. p-Cresyl sulfate

Clinical studies have identified an association between elevated PCS levels (total and unbound) and cardiovascular complications in CKD patients. These cardiovascular complications include an increased rate of coronary artery disease, vascular calcifications, and cardiovascular and all-cause mortality [78, 79, 80, 81, 82].

Cell culture and isolated tissue studies have demonstrated a variety of effects of increased levels of PCS. Several studies have focused on the oxidative stress that results from PCS exposure. Elevated PCS levels have been demonstrated to induce leukocyte-free radical production, oxidative stress in both human umbilical vein endothelial cells and vascular smooth muscle cells, as well as increase NADPH oxidase activity and ROS production in cardiomyocytes leading to cardiac cell apoptosis [83, 84, 85, 86]. Other effects include the release of endothelial microparticles, vascular remodeling, and the observation that an increase in PCS appears to stimulate leukocyte rolling along the vascular endothelium, suggesting there is cross talk between leukocytes and endothelial cells [85, 87, 88]. The mechanisms behind these findings are not yet clear.


5. Potential therapeutic interventions

In response to the mounting evidence that supraphysiological levels of URS likely contribute to the morbidity and mortality of CKD/ESRD, there has been significant interest in developing methods to lower URS levels. Two major approaches have substantial research behind them—increasing removal via dialysis and decreasing production by gastrointestinal flora. Broadly speaking, both have shown the ability to lower URS levels, but no method has definitively shown a mortality benefit as of yet.

5.1. Dialysis

There have been several investigational strategies that have proven successful in removing protein-bound URS during hemodialysis. The method with the fewest obstacles to being incorporated into clinical practice is the addition of a pressure gradient across the dialysis membrane (otherwise known as convection). Despite data indicating that it can effectively remove more protein-bound solutes than traditional dialysis, the clinical benefits have yet to be proven [4, 89, 90]. Another area of research concerns altering the dialysis milieu in order to affect the binding of URS to plasma proteins. Examples of this effort which have data supporting their use include using hypertonic solution, the use of albumin-binding site competitors such as tryptophan and docosahexaenoic acid, increasing temperature, plasma dilutions, and pH manipulation of the dialysate [47, 90, 91, 92, 93, 94].

Other techniques have been proposed and studied, but they involve technologies which would profoundly alter the way dialysis is delivered, therefore making their incorporation into clinical practice more difficult. Given the importance of renal tubular secretion in protein-bound URS removal, there has been interest in incorporating bioengineered renal tubules in the dialysis membrane. In vitro data has demonstrated that secretion of protein-bound URS (indoxyl sulfate and kynurenic acid) can be achieved in immortalized proximal tubule epithelial cells by integrating transport proteins such as organic anion transporters (OAT) [95]. The use of sorbent containing extracorporeal devices (SCED) uses an additional circuit within the hemodialysis setup to cleanse albumin of URS before returning them to circulation. The use of SCEDs has even demonstrated effective removal of these solutes from post-dialysis patient plasma. However, this strategy has been limited due to biocompatibility problems with the sorbent, although the development of newer sorbents may circumnavigate this obstacle [96, 97].

5.2. The gut-kidney axis

There is growing interest in affecting URS levels by intervening at the level of the gut-kidney axis. This approach has significant potential because URS accumulate in all stages of CKD, not just in dialysis-dependent ESRD. By intervening upstream in the gut-kidney axis, clinicians could empirically inhibit the production and absorption of URS and their potential cardiovascular effects. The major strategies being investigated in this area include those that affect URS generation and those that act as gastrointestinal adsorbents. Altering URS generation involves using either probiotics or prebiotics to theoretically shift microbial metabolism toward carbohydrate metabolism and away from the generation of proteolytic fermentation end products such as URS.

The administration of live microorganisms in order to alter an individual’s microbiome (otherwise known as probiotics) has been utilized as a treatment for various illnesses. While some initial studies utilizing probiotics showed a promise in decreasing URS, these studies were performed in patients with healthy kidneys. Only a few studies were performed which looked at URS in CKD patients, and the results for Lactobacillus and Bifidobacterium genera have been promising [98, 99, 100, 101, 102]. As opposed to introducing a living organism, prebiotics are selectively fermented molecules that result in changes to the composition or activity of the gut microbiota, conferring a benefit to the host. The limited studies that exist in utilizing prebiotics have used ingredients belonging to either the inulin-type fructans or the galacto-oligosaccharides [99, 103].

Due to the advancement of DNA sequencing technology, research on the gut microbiome has accelerated and includes many different conditions. The effect of the gut microbiome on URS production has been studied. Nazzal et al. demonstrated the effect of oral vancomycin on the gut microbiome [104]. They demonstrated that plasma levels of protein-bound indoxyl sulfate and p-cresyl sulfate were reduced in an ESRD population after a single dose of oral vancomycin, but the effect was transient and reversed itself by the end of the follow-up period. The diversity of the gut microbiome was significantly reduced, and the effect did not resolve by the end of the study period.

Limiting the uptake of colonic solutes by using an oral adsorbent, such as the spherical carbon adsorbent AST-120, has been an additional approach to lowering URS levels. AST-120 binds to a number of URS precursor molecules, and some of the initial studies were very promising, showing a decrease in the levels of several URS, including IS and PCS [105, 106, 107]. A randomized controlled trial was performed in CKD patients, which sought to evaluate the effect of AST-120 on intima-media thickness and carotid artery stiffness. The results were encouraging, finding that the AST-120 group had reduced intima-media thickness along with less arterial stiffness compared to the non-AST-120 group [108]. However, EPICC (a large randomized, placebo-controlled, double-blind study) failed to show a benefit of AST-120 for clinical outcomes such as CKD progression and mortality, thereby failing to support the widespread use of AST-120 in advanced CKD [109].


6. Future directions

To this day, our understanding of URS is limited. One major limitation of uremia research is that URS accumulate in synchrony. This makes it difficult to establish a causal relationship. Ideally, URS research should be performed in the early CKD population and should include long follow-up. Another limitation is the lack of targeted methods to decrease the level of a specific URS. Once specific URS can be targeted, prospective randomized control trials will able to elucidate each URS’ true effects.

In addition, it is becoming clear that interventions outside of the realm of hemodialysis could have great potential. As described above, URS accumulate in all stages of CKD, not just in dialysis-dependent ESRD. Considering the prevalence of early CKD and its significant mortality, this would be the ideal population for further research on therapeutic options. By focusing on the gut-kidney axis, we could learn how to halt the production of URS. There is a need for randomized control trials to evaluate the effectiveness of prebiotics, probiotics, dietary alterations, adsorbents, and antibiotics in leading to better outcomes for this patient population.


  1. 1. Keith DS, Nichols GA, Guillion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Archives of Internal Medicine. 2004;164(6):659-663
  2. 2. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. New England Journal of Medicine. 1974;290(13):697-701
  3. 3. Vanholder R, Smet RD, Glorieux G, Argilés A, Baurmeister U, Brunet P, et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney International. 2003;63(5):1934-1943
  4. 4. Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G. An update on uremic toxins. International Urology and Nephrology. 2012;45(1):139-150
  5. 5. Gotch F. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrology, Dialysis, Transplantation. 1998 Jan;13(90006):10-14
  6. 6. Lau WL, Vaziri ND. Urea, a true uremic toxin: The empire strikes back. Clinical Science. 2016;131(1):3-12
  7. 7. Johnson WJ, Hagge WW, Wagoner RD, Dinapoli RP, Rosevear JW. Effects of urea loading in patients with far-advanced renal failure. Mayo Clinic Proceedings 1972;47:21-29
  8. 8. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. New England Journal of Medicine. 2002;347(25):2010-2019
  9. 9. Trécherel E, Godin C, Louandre C, Benchitrit J, Poirot S, Mazière JC, et al. Upregulation of BAD, a pro-apoptotic protein of the BCL2 family, in vascular smooth muscle cells exposed to uremic conditions. Biochemical and Biophysical Research Communications. 2012;417(1):479-483
  10. 10. Levey AS. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Annals of Internal Medicine. 1999;130(6):461-70
  11. 11. Leiper J. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovascular Research. 1999;43(3):542-548
  12. 12. Zoccali C, Benedetto FA, Maas R, et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. Journal of the American Society of Nephrology. 2002;13:490-496
  13. 13. Boger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “l-arginine paradox” and acts as a novel cardiovascular risk factor. Journal of Nutrition 2004;134:2842S-2847S
  14. 14. Tanaka M. Dimethylarginine dimethylaminohydrolase overexpression suppresses graft coronary artery disease. Circulation. 2005;112(11):1549-1556
  15. 15. Velasquez M, Ramezani A, Manal A, Raj D. Trimethylamine N-oxide: The good, the bad and the unknown. Toxins. 2016 Aug;8(11):E326
  16. 16. Ma G, Pan B, Chen Y, Guo C, Zhao M, Zheng L, et al. Trimethylamine N-oxide in atherogenesis: Impairing endothelial self-repair capacity and enhancing monocyte adhesion. Bioscience Reports. 2017 Feb;37(2):BSR20160244
  17. 17. Hai X, Landeras V, Dobre MA, Deoreo P, Meyer TW, Hostetter TH. Mechanism of prominent trimethylamine oxide (TMAO) accumulation in hemodialysis patients. PLoS One. 2015 Sep;10(12)
  18. 18. Miyaoka T, Mochizuki T, Takei T, Tsuchiya K, Nitta K. Serum uric acid levels and long-term outcomes in chronic kidney disease. Heart and Vessels. 2013 Sep;29(4):504-512
  19. 19. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS. Uric acid and incident kidney disease in the community. Journal of the American Society of Nephrology. 2008 Dec;19(6):1204-1211
  20. 20. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, et al. Uric acid and long-term outcomes in CKD. American Journal of Kidney Diseases. 2009;53(5):796-803
  21. 21. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. New England Journal of Medicine. 2008;359(17):1811-1821
  22. 22. Levy GD, Rashid N, Niu F, Cheetham TC. Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. The Journal of Rheumatology. 2014 Jan;41(5):955-962
  23. 23. Wang H, Wei Y, Kong X, Xu D. Effects of urate-lowering therapy in hyperuricemia on slowing the progression of renal function: A meta-analysis. Journal of Renal Nutrition. 2013;23(5):389-396
  24. 24. Wilcken DE, Sim AS, Wang J, Wang XL. Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism. Molecular Genetics and Metabolism. 2007;91(4):309-317
  25. 25. Zumrutdal A. Role of β2-microglobulin in uremic patients may be greater than originally suspected. World Journal of Nephrology. 2015;4(1):98-104
  26. 26. Cheung AK. Effects of high-flux hemodialysis on clinical outcomes: Results of the HEMO study. Journal of the American Society of Nephrology. 2003 Jan;14(12):3251-3263
  27. 27. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994;372(6505):425-432
  28. 28. Halaas J, Gajiwala K, Maffei M, Cohen S, Chait B, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269(5223):543-546
  29. 29. Sharma K, Considine RV, Michael B, Dunn SR, Weisberg LS, Kurnik BR, et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney International. 1997;51(6):1980-1985
  30. 30. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH. Role of leptin and melanocortin signaling in uremia-associated cachexia. Journal of Clinical Investigation. 2005 Jan;115(6):1659-1665
  31. 31. Sudlow G, Birkett DJ, Wade DN. The characterization of two specific drug binding sites on human serum albumin. Molecular Pharmacology. 1975;11(6):824-832
  32. 32. Niwa T, Takeda N, Maeda K, Shibata M, Tatematsu A. Accumulation of furancarboxylic acids in uremic serum as inhibitors of drug binding. Clinica Chimica Acta. 1988;173(2):127-138
  33. 33. Tsutsumi Y. Renal disposition of a furan dicarboxylic acid and other uremic toxins in the rat. Journal of Pharmacology and Experimental Therapeutics. 2002 Jan;303(2):880-887
  34. 34. Viaene L, Meijers BKI, Bammens B, Vanrenterghem Y, Evenepoel P. Serum concentrations of p-cresyl sulfate and indoxyl sulfate, but not inflammatory markers, increase in incident peritoneal dialysis patients in parallel with loss of residual renal function. Peritoneal Dialysis International. 2013;34(1):71-78
  35. 35. Nigam SK, Wu W, Bush KT, Hoenig MP, Blantz RC, Bhatnagar V. Handling of drugs, metabolites, and uremic toxins by kidney proximal tubule drug transporters. Clinical Journal of the American Society of Nephrology. 2015;10(11):2039-2049
  36. 36. Deguchi T, Ohtsuki S, Otagiri M, Takanaga H, Asaba H, Mori S, et al. Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney International. 2002;61(5):1760-1768
  37. 37. Wikoff WR, Nagle MA, Kouznetsova VL, Tsigelny IF, Nigam SK. Untargeted metabolomics identifies enterobiome metabolites and putative uremic toxins as substrates of organic anion transporter 1 (Oat1). Journal of Proteome Research. 2011 Mar;10(6):2842-2851
  38. 38. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T. Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Analytical and Bioanalytical Chemistry. 2012;403(7):1841-1850
  39. 39. Niwa T, Yazawa T, Kodama T, Uehara Y, Maeda K, Yamada K. Efficient removal of albumin-bound furancarboxylic acid, an inhibitor of erythropoiesis, by continuous ambulatory peritoneal dialysis. Nephron. 2008 Oct;56(3):241-245
  40. 40. Lim CF, Bernard BF, Jong MD, Docter R, Krenning EP, Hennemann G. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. The Journal of Clinical Endocrinology & Metabolism. 1993;76(2):318-324
  41. 41. Wang Q, Liu D, Song P, Zou MH. Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation. Frontiers in Bioscience. 2015;20(7):1116-1143
  42. 42. Schwarcz R, Pellicciari R. Manipulation of brain kynurenines: Glial targets, neuronal effects, and clinical opportunities. Journal of Pharmacology and Experimental Therapeutics. 2002 Jan;303(1):1-10
  43. 43. Stone TW. Neuropharmacology of quinolinic and kynurenic acids. Pharmacological Reviews. 1993;45(3):309-379
  44. 44. Pawlak D, Koda M, Pawlak S, Wolczynski S, Buczko W. Contribution of quinolinic acid in the development of anemia in renal insufficiency. American Journal of Physiology: Renal Physiology. 2002 Mar;284(4):693-700
  45. 45. Meijers BKI, Loor HD, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clinical Journal of the American Society of Nephrology. 2009;4(12):1932-1938
  46. 46. Liabeuf S, Drüeke TB, Massy ZA. Protein-bound uremic toxins: New insight from clinical studies. Toxins. 2011;3(12):911-919
  47. 47. Yamamoto KI, Eguchi K, Kaneko I, Akiba T, Mineshima M. In vitro study of removal of protein-bound toxins. Blood Purification. 2013;35(s1):51-54
  48. 48. Jhawar S, Singh P, Torres D, Ramirez-Valle F, Kassem H, Banerjee T, et al. Functional genomic analysis identifies indoxyl sulfate as a major, poorly dialyzable uremic toxin in end-stage renal disease. PLoS One. 2015;10(3):e0118703
  49. 49. Meijers B, Glorieux G, Poesen R, Bakker SJ. Nonextracorporeal methods for decreasing uremic solute concentration: A future way to go? Seminars in Nephrology. 2014;34(2):228-243
  50. 50. Wikoff WR, Anfora AT, Liu J, Schultz PG, Lesley SA, Peters EC, et al. Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. Proceedings of the National Academy of Sciences. 2009;106(10):3698-3703
  51. 51. Evenepoel P, Meijers BKI, Bammens BRM, Verbeke K. Uremic toxins originating from colonic microbial metabolism. Kidney International. 2009;76(S114):S12-S19
  52. 52. Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, et al. Colonic contribution to uremic solutes. Journal of the American Society of Nephrology. 2011;22(9):1769-1776
  53. 53. Leong S, Sirich T. Indoxyl sulfate—Review of toxicity and therapeutic strategies. Toxins. 2016;8(12):358
  54. 54. Schepers E, Glorieux G, Vanholder R. The gut: The forgotten organ in uremia? Blood Purification. 2010;29(2):130-136
  55. 55. Meijers BKI, Evenepoel P. The gut-kidney axis: Indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrology, Dialysis, Transplantation. 2011;26(3):759-761
  56. 56. Evenepoel P, Poesen R, Meijers B. The gut-kidney axis. Pediatric Nephrology. 2016. DOI: 10.1007/s00467-016-3527-x
  57. 57. Cummings JH, Hill MJ, Bone ES, Branch WJ, Jenkins DJ. The effect of meat protein and dietary fiber on colonic function and metabolism. II. Bacterial metabolites in feces and urine. American Journal of Clinical Nutrition. 1979;32(10):2094-2101
  58. 58. Sato B, Yoshikawa D, Ishii H, Suzuki S, Inoue Y, Takeshita K, et al. Relation of plasma indoxyl sulfate levels and estimated glomerular filtration rate to left ventricular diastolic dysfunction. The American Journal of Cardiology. 2013;111(5):712-716
  59. 59. Shimazu S, Hirashiki A, Okumura T, Yamada T, Okamoto R, Shinoda N, et al. Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circulation Journal. 2013;77(2):390-396
  60. 60. Hsu CC, Lu YC, Chiu CA, Yu TH, Hung WC, Wang CP, et al. Levels of indoxyl sulfate are associated with severity of coronary atherosclerosis. Clinical and Investigative Medicine. 2013 Feb;36(1):E42-E49
  61. 61. Tsai ML, Hsieh IC, Hung CC, Chen CC. Serum free indoxyl sulfate associated with in-stent restenosis after coronary artery stentings. Cardiovascular Toxicology. 2014;15(1):52-60
  62. 62. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate Is associated with vascular disease and mortality in chronic kidney disease patients. Clinical Journal of the American Society of Nephrology. 2009;4(10):1551-1558
  63. 63. Lin CJ, Liu HL, Pan CF, Chuang CK, Jayakumar T, Wang TJ, et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Archives of Medical Research. 2012;43(6):451-456
  64. 64. Shafi T, Meyer TW, Hostetter TH, Melamed ML, Parekh RS, Hwang S, et al. Free levels of selected organic solutes and cardiovascular morbidity and mortality in hemodialysis patients: Results from the Retained Organic Solutes and Clinical Outcomes (ROSCO) investigators. PLoS One. 2015 Apr;10(5)
  65. 65. Lin CJ, Wu CJ, Pan CF, Chen YC, Sun FJ, Chen HH. Serum protein-bound uraemic toxins and clinical outcomes in haemodialysis patients. Nephrology, Dialysis, Transplantation. 2010;25(11):3693-3700
  66. 66. Gondouin B, Cerini C, Dou L, Sallée M, Duval-Sabatier A, Pletinck A, et al. Indolic uremic solutes increase tissue factor production in endothelial cells by the aryl hydrocarbon receptor pathway. Kidney International. 2013;84(4):733-744
  67. 67. Chitalia VC, Shivanna S, Martorell J, Balcells M, Bosch I, Kolandaivelu K, et al. Uremic serum and solutes increase post-vascular interventional thrombotic risk through altered stability of smooth muscle cell tissue factor. Circulation. 2012;127(3):365-376
  68. 68. Wu D, Nishimura N, Kuo V, Fiehn O, Shahbaz S, Winkle LV, et al. Activation of aryl hydrocarbon receptor induces vascular inflammation and promotes atherosclerosis in apolipoprotein E-/- mice. Arteriosclerosis, Thrombosis, and Vascular Biology. 2011;31(6):1260-1267
  69. 69. Ito S, Osaka M, Higuchi Y, Nishijima F, Ishii H, Yoshida M. Indoxyl sulfate induces leukocyte-endothelial interactions through up-regulation of E-selectin. Journal of Biological Chemistry. 2010 Nov;285(50):38869-38875
  70. 70. Shen WC, Liang CJ, Huang TM, Liu CW, Wang SH, Young GH, et al. Indoxyl sulfate enhances IL-1β-induced E-selectin expression in endothelial cells in acute kidney injury by the ROS/MAPKs/NFκB/AP-1 pathway. Archives of Toxicology. 2015 Dec;90(11):2779-2792
  71. 71. Adijiang A, Goto S, Uramoto S, Nishijima F, Niwa T. Indoxyl sulphate promotes aortic calcification with expression of osteoblast-specific proteins in hypertensive rats. Nephrology, Dialysis, Transplantation. 2008 Jul;23(6):1892-1901
  72. 72. Nii-Kono T, Iwasaki Y, Uchida M, Fujieda A, Hosokawa A, Motojima M, et al. Indoxyl sulfate induces skeletal resistance to parathyroid hormone in cultured osteoblastic cells. Kidney International. 2007;71(8):738-743
  73. 73. Peng YS, Lin YT, Chen Y, Hung KY, Wang SM. Effects of indoxyl sulfate on adherens junctions of endothelial cells and the underlying signaling mechanism. Journal of Cellular Biochemistry. 2012;113(3):1034-1043
  74. 74. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney International. 2004;65(2):442-451
  75. 75. Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. Journal of Thrombosis and Haemostasis. 2006;4(3):566-573
  76. 76. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-κB and free radical in proximal tubular cells. Kidney International. 2003;63(5):1671-1680
  77. 77. Lin CJ, Lin J, Pan CF, Chuang CK, Liu HL, Sun FJ, et al. Indoxyl sulfate, not p-cresyl sulfate, is associated with advanced glycation end products in patients on long-term hemodialysis. Kidney and Blood Pressure Research. 2015;40(2):121-129
  78. 78. Wang CP, Lu LF, Yu TH, Hung WC, Chiu CA, Chung FM, et al. Serum levels of total p-cresylsulphate are associated with angiographic coronary atherosclerosis severity in stable angina patients with early stage of renal failure. Atherosclerosis. 2010;211(2):579-583
  79. 79. Chiu CA, Lu LF, Yu TH, Hung WC, Chung FM, Tsai IT, et al. Increased levels of total p-cresylsulphate and indoxyl sulphate are associated with coronary artery disease in patients with diabetic nephropathy. The Review of Diabetic Studies. 2010;7(4):275-284
  80. 80. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrology, Dialysis, Transplantation. 2009;25(4):1183-1191
  81. 81. Wu IW, Hsu KH, Hsu HJ, Lee CC, Sun CY, Tsai CJ, et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients—A prospective cohort study. Nephrology, Dialysis, Transplantation. 2011 Feb;27(3):1169-1175
  82. 82. Lin CJ, Wu V, Wu PC, Wu CJ. Meta-analysis of the associations of p-cresyl sulfate (PCS) and indoxyl sulfate (IS) with cardiovascular events and all-cause mortality in patients with chronic renal failure. PLoS One. 2015;10(7)
  83. 83. Schepers E, Meert N, Glorieux G, Goeman J, Eycken JVD, Vanholder R. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrology, Dialysis, Transplantation. 2006 Feb;22(2):592-596
  84. 84. Meert N, Schepers E, Glorieux G, Landschoot MV, Goeman JL, Waterloos M-A, et al. Novel method for simultaneous determination of p-cresylsulphate and p-cresylglucuronide: Clinical data and pathophysiological implications. Nephrology, Dialysis, Transplantation. 2011;27(6):2388-2396
  85. 85. Meijers BK, Kerckhoven SV, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. American Journal of Kidney Diseases. 2009;54(5):891-901
  86. 86. Han H, Zhu J, Zhu Z, Ni J, Du R, Dai Y, et al. p-Cresyl sulfate aggravates cardiac dysfunction associated with chronic kidney disease by enhancing apoptosis of cardiomyocytes. Journal of the American Heart Association. 2015 Nov;4(6):e001852
  87. 87. Gross P, Massy ZA, Henaut L, Boudot C, Cagnard J, March C, et al. Para-cresyl sulfate acutely impairs vascular reactivity and induces vascular remodeling. Journal of Cellular Physiology. 2015;230(12):2927-2935
  88. 88. Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Landschoot MV, et al. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. Journal of the American Society of Nephrology. 2013 May;24(12):1981-1994
  89. 89. Meert N, Eloot S, Schepers E, Lemke HD, Dhondt A, Glorieux G, et al. Comparison of removal capacity of two consecutive generations of high-flux dialysers during different treatment modalities. Nephrology, Dialysis, Transplantation. 2011 Oct;26(8):2624-2630
  90. 90. Meert N, Eloot S, Waterloos MA, Landschoot MV, Dhondt A, Glorieux G, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: A prospective trial. Nephrology, Dialysis, Transplantation. 2008 Jul;24(2):562-570
  91. 91. Böhringer F, Jankowski V, Gajjala PR, Zidek W, Jankowski J. Release of uremic retention solutes from protein binding by hypertonic predilution hemodiafiltration. ASAIO Journal. 2015;61(1):55-60
  92. 92. Tao X, Thijssen S, Levin N, Kotanko P, Handelman G. Enhanced indoxyl sulfate dialyzer clearance with the use of binding competitors. Blood Purification. 2015;39(4):323-330
  93. 93. Devine E, Krieter D, Rüth M, Jankovski J, Lemke HD. Binding affinity and capacity for the uremic toxin indoxyl sulfate. Toxins. 2014;6(2):416-430
  94. 94. Tange Y, Takesawa S, Yoshitake S. Dialysate with high dissolved hydrogen facilitates dissociation of indoxyl sulfate from albumin. Nephro-Urology Monthly. 2015;7(2)
  95. 95. Jansen J, Fedecostante M, Wilmer MJ, Peters JG, Kreuser UM, Broek PHVD, et al. Bioengineered kidney tubules efficiently excrete uremic toxins. Scientific Reports. 2016;6:26715
  96. 96. Sandeman SR, Howell CA, Phillips GJ, Zheng Y, Standen G, Pletzenauer R, et al. An adsorbent monolith device to augment the removal of uraemic toxins during haemodialysis. Journal of Materials Science: Materials in Medicine. 2014;25(6):1589-1597
  97. 97. Meijers BK, Weber V, Bammens B, Dehaen W, Verbeke K, Falkenhagen D, et al. Removal of the uremic retention solute p-cresol using fractionated plasma separation and adsorption. Artificial Organs. 2008;32(3):214-219
  98. 98. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron. 1996;74(2):349-355
  99. 99. Nakabayashi I, Nakamura M, Kawakami K, Ohta T, Kato I, Uchida K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: A preliminary study. Nephrology, Dialysis, Transplantation. 2010 Jul;26(3):1094-1098
  100. 100. Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Advances in Therapy. 2010;27(9):634-647
  101. 101. Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. American Journal of Kidney Diseases. 2003;41(3):S142-S145
  102. 102. Taki K, Takayama F, Niwa T. Beneficial effects of Bifidobacteria in a gastroresistant seamless capsule on hyperhomocysteinemia in hemodialysis patients. Journal of Renal Nutrition. 2005;15(1):77-80
  103. 103. Meijers BKI, Preter VD, Verbeke K, Vanrenterghem Y, Evenepoel P. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrology, Dialysis, Transplantation. 2009;25(1):219-224
  104. 104. Nazzal L, Roberts J, Singh P, Jhawar S, Matalon A, Gao Z, et al. Microbiome perturbation by oral vancomycin reduces plasma concentration of two gut-derived uremic solutes, indoxyl sulfate and p-cresyl sulfate, in end-stage renal disease. Nephrology, Dialysis, Transplantation. 2017;1-9. DOI: 10.1093/ndt/gfx029
  105. 105. Lee CT, Hsu CY, Tain YL, Ng HY, Cheng BC, Yang CC, et al. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients. Blood Purification. 2014;37(1):76-83
  106. 106. Kikuchi K, Itoh Y, Tateoka R, Ezawa A, Murakami K, Niwa T. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. Journal of Chromatography B. 2010;878(29):2997-3002
  107. 107. Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD. American Journal of Kidney Diseases. 2006;47(4):565-577
  108. 108. Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada N, Ebihara I, et al. Oral adsorbent AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure. Kidney and Blood Pressure Research. 2004 Mar;27(2):121-126
  109. 109. Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. Journal of the American Society of Nephrology. 2014;26(7):1732-1746

Written By

William Ackley, Leland Soiefer, Aleksey Etinger and Jerome Lowenstein

Submitted: 13 March 2017 Reviewed: 24 July 2017 Published: 20 December 2017